Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
August 6, 2001
- Council Recommends Abolition of \205 Rule, Review of NHI Pricing Rule
August 6, 2001
- DIAGNOSTIC NEWS IN BRIEF
August 6, 2001
- Nippon Shinyaku to Focus on Unmet Market Needs: New President Hatsuyama
August 6, 2001
- 119 Voluntary Recalls of Drugs Reported in FY2000
August 6, 2001
- MEDICAL DEVICE NEWS IN BRIEF
August 6, 2001
- Nippon Chemiphar to Shift from Restructuring to Business Expansion: President Yamaguchi
August 6, 2001
- Mechanisms for Cancer Onset, Metastasis Expected to Be Clarified in 2014: Monkasho Survey
August 6, 2001
- Wishing to Launch Drugs in Japan within 6 Months of the 1st Launch Overseas: Dr Kato of AstraZeneca
August 6, 2001
- GSK, Shionogi to Establish Overseas Joint Venture
August 6, 2001
- REGULATORY NEW IN BRIEF
August 6, 2001
- Taiho Aims at Becoming World Leader in Oncology: Mid-term Plan
August 6, 2001
- Blood Glucose Control Improved by Ultra-fast Acting Insulin: Lilly Symposium
August 6, 2001
- Nippon Kayaku to Place Top Priority on R&D
August 6, 2001
- Large Studies Required to Verify Inhibition of Cardiovascular Events: Sankyo Seminar
August 6, 2001
- Morishita Jintan to Expand Seamless Microcapsule Business
August 6, 2001
- Saitama Medical School to Establish Genomic Medicine Research Center
August 6, 2001
- Pfizer to Increase Number of MRs to 2,300 in 2005: Survey
August 6, 2001
- Many Physicians Prescribe Medium/High-Dose Pill: User Education Needed
August 6, 2001
- BUSINESS NEWS IN BRIEF
August 6, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…